Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.

Tveita A, Fauskanger M, Bogen B, Haabeth OA.

Oncotarget. 2016 Oct 11;7(41):67175-67182. doi: 10.18632/oncotarget.11946.

2.

Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.

Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B.

Cancer Res. 2009 Jul 15;69(14):5901-7. doi: 10.1158/0008-5472.CAN-08-4816. Epub 2009 Jun 30.

3.

Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.

Dembic Z, Schenck K, Bogen B.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2697-702.

4.

Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.

Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B.

Cancer Res. 2015 Aug 15;75(16):3268-78. doi: 10.1158/0008-5472.CAN-14-3640. Epub 2015 Jun 2.

6.

CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II.

Pietra BA, Wiseman A, Bolwerk A, Rizeq M, Gill RG.

J Clin Invest. 2000 Oct;106(8):1003-10.

9.

Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.

Matsuzaki J, Tsuji T, Luescher I, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Cancer Immunol Res. 2014 Apr;2(4):341-50. doi: 10.1158/2326-6066.CIR-13-0138. Epub 2013 Dec 17.

10.

Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.

Corthay A, Lorvik KB, Bogen B.

Scand J Immunol. 2011 Jun;73(6):527-30. doi: 10.1111/j.1365-3083.2011.02558.x. Review.

11.

A mouse model for immunotherapy of myeloma.

Bogen B.

Hematol J. 2002;3(5):224-9.

PMID:
12391539
13.
14.

Two levels of help for B cell alloantibody production.

Steele DJ, Laufer TM, Smiley ST, Ando Y, Grusby MJ, Glimcher LH, Auchincloss H Jr.

J Exp Med. 1996 Feb 1;183(2):699-703.

15.

MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.

Ilkovitch D, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2004 Jun;53(6):525-32. Epub 2004 Jan 17.

PMID:
14730400
16.

Primary antitumor immune response mediated by CD4+ T cells.

Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B.

Immunity. 2005 Mar;22(3):371-83.

17.

Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.

Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA.

Int J Cancer. 1994 Jul 1;58(1):69-79.

PMID:
7516926

Supplemental Content

Support Center